<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04494945</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00020629</org_study_id>
    <secondary_id>NCI-2020-04627</secondary_id>
    <secondary_id>STUDY00020629</secondary_id>
    <secondary_id>U01CA232819</secondary_id>
    <nct_id>NCT04494945</nct_id>
  </id_info>
  <brief_title>Identifying and Caring for Individuals With Inherited Cancer Syndrome</brief_title>
  <official_title>Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial examines approaches to identify and care for individuals with inherited cancer&#xD;
      syndrome. The purpose of this study is to offer no cost genetic testing to the general&#xD;
      public. Researchers hope to learn the value of providing broad, public-wide testing for high&#xD;
      risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of&#xD;
      only testing people whose families are known to be high risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate the effectiveness and sustainability of heritable cancer syndrome testing in two&#xD;
      proposed screening populations compared to current guidelines.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Measure adherence to current guidelines for screening and prophylactic intervention of&#xD;
      Cohorts B and C compared to Cohort A to show non-inferiority.&#xD;
&#xD;
      II. Measure the efficiency of cascade testing (defined as the ratio of family members&#xD;
      screened over total possible) for Cohorts B and C compared to Cohort A to show&#xD;
      non-inferiority.&#xD;
&#xD;
      III. Determine the costs and effectiveness, specifically quality adjusted life years (QALYs)&#xD;
      associated with genetic screening models based on Cohorts B and C to estimate incremental&#xD;
      cost-effectiveness ratio (ICER) and show that the costs per QALY are below the acceptable&#xD;
      cost effectiveness threshold.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo collection of saliva samples for genetic testing. If genetic test is&#xD;
      positive, patients receive genetic counseling. Patients also complete a survey about cancer&#xD;
      prevention, screening, and treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">June 10, 2030</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness and sustainability of heritable cancer syndrome testing in the two novel testing populations</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Determine the costs and effectiveness, specifically Quality Adjusted Life Years (QALYs) associated with genetic screening models based on Cohorts B and C to estimate incremental cost-effectiveness ratio (ICER) and show that the costs per QALY are below the acceptable cost effectiveness threshold.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to standard of care for hereditary breast and ovarian cancer (HBOC) and Lynch syndromes</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>For Lynch syndrome we identify compliance as colonoscopy in past two years and bilateral salpingo-oophorectomy (BSO ) after child-bearing age. For HBOC, compliance is defined as breast imaging in past year or risk reducing surgery at any point in women.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Merged risk reduction strategies of bilateral salpingo-oophorectomy (BSO) or bilateral mastectomy and imaging</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The merged risk reduction strategies of BSO or bilateral mastectomy and the imaging are treated as evidence of risk reducing behavior.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cascade screening rate among Lynch or HBOC positive carriers</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will conduct negative binomial regression model and non-inferiority will be determined by rate ratio and its 95% confidence interval (CI).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27500</enrollment>
  <condition>BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome</condition>
  <condition>Breast Ductal Carcinoma In Situ</condition>
  <condition>Hematopoietic and Lymphoid System Neoplasm</condition>
  <condition>Hereditary Neoplastic Syndrome</condition>
  <condition>Lynch Syndrome</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of saliva sample</description>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
    <other_name>Biological Sample Collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Counseling</intervention_name>
    <description>Receive genetic counseling if testing results are positive</description>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Undergo genetic testing</description>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
    <other_name>genetic analysis</other_name>
    <other_name>Genetic Examination</other_name>
    <other_name>Genetic Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Complete a survey</description>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALL COHORTS: 18 years of age or older&#xD;
&#xD;
          -  COHORT A: Per Health Insurance Portability and Accountability Act (HIPAA) waiver,&#xD;
             Cohort A returns survey as consent&#xD;
&#xD;
          -  COHORT A: Patients may or may not be diagnosed with cancer&#xD;
&#xD;
          -  COHORT A: Patients have received genetic counseling in the past 1 - 2 years&#xD;
&#xD;
          -  COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and/or Lynch&#xD;
             syndrome&#xD;
&#xD;
          -  COHORT A: INCLUSIVE of no contact list to exclude from Cohort B&#xD;
&#xD;
          -  COHORT B: Creation of secure Medable account&#xD;
&#xD;
          -  COHORT B: Consent to this project, either hard or electronic signature&#xD;
&#xD;
          -  COHORT B: Consent to the Healthy Oregon Project (HOP) repository, either hard or&#xD;
             electronic signature&#xD;
&#xD;
          -  COHORT B: Choosing to submit a deoxyribonucleic acid (DNA) sample&#xD;
&#xD;
          -  COHORT B: Patients diagnosed with any National Cancer Institute (NCI)-reportable&#xD;
             cancers, including ductal carcinoma in situ (DCIS) and/or in situ breast cancer&#xD;
&#xD;
          -  COHORT B: Must have had an encounter within past six months&#xD;
&#xD;
          -  COHORT B: Exclude Cohort A&#xD;
&#xD;
          -  COHORT C: Creation of secure Medable account&#xD;
&#xD;
          -  COHORT C: Consent to this project, either hard or electronic signature&#xD;
&#xD;
          -  COHORT C: Consent to the HOP repository, either hard or electronic signature&#xD;
&#xD;
          -  COHORT C: Choosing to submit a DNA sample&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul T Spellman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bill J. Wright, Ph.D.</last_name>
      <email>Bill.Wright@providence.org</email>
    </contact>
    <investigator>
      <last_name>Bill J. Wright, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul T. Spellman, Ph.D.</last_name>
      <phone>503-418-8311</phone>
      <email>spellmap@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul T. Spellman, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Paul T Spellman, Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Neoplastic Syndromes, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

